Skip to main content

Trinity College Dublin, The University of Dublin

Menu Search


Trinity College Dublin By using this website you consent to the use of cookies in accordance with the Trinity cookie policy. For more information on cookies see our cookie policy.

      
Profile Photo

Dr. Michael Gallagher

Research Fellow (Histopathology)
COOMBE WOMENS HOSPITAL


Claudia Gasch, Brendan Ffrench, John O'Leary and Michael F Gallagher, Catching Moving Targets: Cancer Stem Cell Targets, Therapy-Resistance & Considerations for Clinical Targeting, Molecular Cancer, 16, (1), 2017, p43-, Journal Article, PUBLISHED
Sulaiman, G, Cooke A, Ffrench B, Gasch C, Abdullai OA, O'Connor K, Elbaruni S, Blacksheilds G, Spillane C, Keegan H, McEneaney V, Knittel R, Rogers A, Jeffery IB, Doyle B, Bates M, d'Adhemar C, Lee M, Campbell EL, Moynagh P, Higgins DG, O'Toole S, O'Neill L, O'Leary JJ and Gallagher MF. , MyD88 is an essential component of retinoic acid induced differentiation in human pluripotent embryonal carcinoma cells. Cell Death & Differentiation (In Press)., Cell Death and Differentiation, 2017, Journal Article, ACCEPTED
Ffrench B, Gasch, Hokamp K, Spillane C, Blackshields G, Mahgoub TM, Bates M, Kehoe L, Mooney A, Doyle R, Doyle B, O'Donnell D, Gleeson N, Hennessy BT, Stordal B, O'Riain C, Lambkin H, O'Toole S, O'Leary JJ, and Gallagher MF., CD10-/ALDH- cells are the sole cisplatin-resistant component of a novel ovarian cancer stem cell network. Cell Death & Disease , Cell Death and Disease, 2017, Journal Article, ACCEPTED
MacDonagh L, Gallagher MF, Ffrench B, Gasch C et al, Targeting aldehyde dehygrogenase 1 (ALDH1) to circumvent cisplatin resistance in NSCLC, OncoTarget, 2017, Journal Article, ACCEPTED
Lynham-Lennon N, Heavey S, Sommerville G, Bibby B, Ffrench B, Quinn J, Gasch C, O'Leary JJ, Gallagher MF, Reynolds J and Maher S, microRNA-17 is downregulated in esophageal adenocarcinoma cancer stem cells and promotes a radioresistant phenotype, OncoTarget, 8, (7), 2017, p11400 - 11413, Journal Article, PUBLISHED
Cancer stem cells: targeting the sub-populations with epigenetic agents. in, editor(s)Steven Gray , Epigenetic Cancer Therapy, Elsevier, 2015, [Brendan Ffrench, John O'Leary and Michael F Gallagher], Book Chapter, PUBLISHED
McEvoy, L.M., O'Toole, S.A., Spillane, C.D., Martin, C.M., Gallagher, M.F., Stordal, B., Blackshields, G., Sheils, O., O'Leary, J.J., Identifying novel hypoxia-associated markers of chemoresistance in ovarian cancer, BMC Cancer, 15, (1), 2015, p547-, Journal Article, PUBLISHED  TARA - Full Text  DOI
Gallagher MF, Salley V, Spillane C, Ffrench B, Martin C, Sheils O, Watson W and O'Leary JJ. , Regulation of Cell Cycle and Suppression of Osteoblast Differentiation Mechanisms by Prostate Cancer Stem-Like Holoclones, Journal of Clinical Pathology, 1, 2015, p11-, Journal Article, PUBLISHED
Ffrench B, Gasch C, O'Leary JJ, Gallagher MF, Developing ovarian cancer stem cell models: laying the pipeline from discovery to clinical intervention., Molecular cancer, 13, 2014, p262 , Journal Article, PUBLISHED  TARA - Full Text  DOI
d'Adhemar CJ, Spillane CD, Gallagher MF, Bates M, Costello KM, Barry-O'Crowley J, Haley K, Kernan N, Murphy C, Smyth PC, O'Byrne K, Pennington S, Cooke AA, Ffrench B, Martin CM, O'Donnell D, Hennessy B, Stordal B, Finn S, McCann A, Gleeson N, D'Arcy T, Flood B, O'Neill LA, Sheils O, O'Toole S, O'Leary JJ, The MyD88+ phenotype is an adverse prognostic factor in epithelial ovarian cancer., PloS one, 9, (6), 2014, pe100816 , Journal Article, PUBLISHED  TARA - Full Text  DOI
  

Page 1 of 2

  

Award Date
Project Licence Holder, LAST Ireland (Animal Research) 2011-Present
Guest Lecturer (Stem & Cancer Stem Cell Biology), Maynooth University 2014